Select Year
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
MENU
Strategic Plan Questions
Funders
Federal vs. Private
Strategic Plan Multiyear Funding
Strategic Plan Objectives
Subcategories
Geography
About
Question 4: Short-term Objective B
Q4.S.B : Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.
Projects Found: 96
Total Funding: $15,303,589
Display
10
20
30
Records
Autism Science Foundation Endocannabanoid Enhancement of Sociability in Autism-related Mouse Models $0
$0 University of California, Irvine
Autism Science Foundation A Unified Molecular Mechanism Explaining Social Behavior and Oxytocin levels in ASD $25,000
$25,000 Washington University in St. Louis
Autism Speaks Preclinical Autism Consortium for Therapeutics (PACT) $0
$0 University of California, Davis
Autism Speaks Novel approaches to enhance social cognition by stimulating central oxytocin release $0
$0 Emory University
Autism Speaks Preclinical Autism Consortium for Therapeutics (PACT)- Boston Children's Hospital $0
$0 Boston Children's Hospital
National Institutes of Health Pre-clinical evaluation of oxytocin for ASD treatment discovery $244,898
$244,898 University of California, Davis
National Institutes of Health Scalable technologies for genome engineering in hIPSCs $341,000
$341,000 University of California, San Diego
National Institutes of Health Formation and Function of Circuitry for Vocal Learning $361,456
$361,456 University of California, Los Angeles
National Institutes of Health Effects of Chronic Intranasal Oxytocin $1,105,938
$1,105,938 University of California, Davis
National Institutes of Health Functional Analysis of Rare Variants in Genes Associated with Autism $147,905
$147,905 Yale University
Interagency Autism Coordinating Committee (IACC)
Autism Research Database (AFD)
Q4.S.B: Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012. 
